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Abstract: Purpose. The management of patients with adrenocortical carcinoma (ACC) is
challenging. As mitotane and chemotherapy show limited efficacy, there is an urgent
need to develop therapeutic approaches. The aim of this study was to investigate the
antitumor activity of progesterone and explore the molecular mechanisms underlying
its cytotoxic effects in the NCI-H295R cell line and  primary cell cultures derived from
ACC patients.
Methods. Cell viability, cell cycle and apoptosis were analyzed in untreated and
progesterone-treated ACC cells. The ability of progesterone to affect the Wnt/β-catenin
pathway in NCI-H295R cells was investigated by immunofluorescence. Progesterone
and mitotane combination experiments were also performed to evaluate their
interaction on NCI-H295R cell viability.
Results. We demonstrated that progesterone exerted a concentration-dependent
inhibition of ACC cell viability. Apoptosis was the main mechanism, as demonstrated
by a significant increase of apoptosis and cleaved-Caspase-3 levels. Reduction of β-
catenin nuclear translocation may contribute to the progesterone cytotoxic effect. The
progesterone antineoplastic activity was synergically increased when mitotane was
added to the cell culture medium.
Conclusions. Our results show that progesterone has antineoplastic activity in ACC
cells. The synergistic cytotoxic activity of progesterone with mitotane provides the
rationale for testing this combination in a clinical study.
Response to Reviewers: Reviewer #1:
1)      Introduction: is there any information on whether mifepristone also blocks the
membranous progesterone receptors?
Mifepristone is generally identified as a “classical” progesterone receptor (PR)
antagonist because it forms complexes with PR and its hormonal regulatory elements
within DNA (J Biol Chem 271:1209-1217, 1996). Its mechanism as a glucocorticoid
and progesterone receptor antagonist  was discovered about 40 years ago, and then
found to be an androgen receptor antagonist as well (Expert Opin Pharmacother
11:481–488, 2010). However, when targeting cells outside the reproductive tract, the
progesterone antagonistic activity of mifepristone is less clear (Hum Reprod 24:1968-
1975, 2009). The role of mifepristone in modulating the effect of progesterone has
become even more complex with the identification of progesterone membrane
receptors (mPRs). This "class" of receptors is still being studied, and its different
components, roles and agonist and antagonist drugs are still being identified. Indeed,
non-genomic effects of mifepristone, as agonist/antagonist of progesterone, were
observed in different cell lines (Anticancer Res 30:4835-4840, 2010; Anticancer Res
29:1047-1052, 2009; Hum Reprod 24:1968-1975, 2009), included cells from the
Central Nervous System, such as Cerebellar Purkinje cells, where it has been
demonstrated that both PRs (genomic effects) and mPRs (PGRMC1 included)  (non-
genomic effects) are involved in the regulation of  neurosteroidogenesis, through the
action of both progesterone and mifepristone, this latter acting as agonist of mPRs in
mature cerebellar Purkinje cells (Cell. Mol. Life Sci 71:1723–1740, 2014) . Despite
these intriguing findings, the mechanism of actions of these non-genomic effects is not
yet completely understood because mifepristone seems to display no binding affinity
for mPRs (Endocrinology 148: 705-718, 2007).
2)      Page 9: P values need to be provided for all results of apoptosis assays  - was %
of apoptotic cells at each time point significantly different to controls?
According to the Reviewer observation,  P values are now reported in the revised Ms
(page 9-10, lines 215-223). Exposure of NCI-H295R cells to 25 µM progesterone for 2,
4 and 6 days, significantly increased the number of apoptotic cells: P < 0.05; P < 0.001
and P < 0.001, respectively.
3)      Page 9: Have the authors tried progesterone treatment on the non-steroidogenic
ACC cell line SW13?
We agree to the Reviewer’s point and we explored the effect of progesterone exposure
in the SW13 cells: SW13 cells expressed mPRs and PRGCM1, while were devoid of
PgRs. Exposure of increasing concentrations of progesterone induced a non
concentration-dependent decrease of SW13 cell viability, suggesting a role of
membrane progesterone receptors in mediating this effect. Results are now reported in
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Supplemental Figure 4, and commented at page 12, lines 274-284. This is an intriguing
result, that deserves to be deepened with further experiments, in order to establish the
exact contribution of the different progesterone receptor components in inducing
reduction of cell viability.
The progesterone mechanism of action thus becomes very complex, also in light of the
evidence showing a different effect of progesterone, depending on many variables,
such as the type of cells, the genomic and/or non genomic effects linked to the
progesterone receptor expression and the concentration of hormone present (reviewed
in Expert Rev Endocrinol Metab. 12(3):187-197, 2017). Accordingly, the non
steroidogenic SW13 cell line represents a different cell phenotype compared to NCI-
H295R cells, as it  has been established from a  grade IV primary  small cell carcinoma
in the adrenal cortex, with  their exact histopathologic characteristics still under
investigation (Mol Cell Endocrinol. 351(1):58-65, 2012).
Although these preliminary results are of interest,  they are  outside the main topic of
this Ms and, indeed, they will be the subject of experiments currently underway in the
laboratory. This point is now underlined in the Ms: page 13, lines 295-308).
4)      Page 10: The numerical result, including p value, should be quoted for the
reported increase in cells in sub-G0 phase
According to the Reviewer suggestion, the numerical result of cells in sub-G0 phase,
and P value, are now reported in the revised Ms (page 10, line 230-231).
5)      Page 10: Were any other of the kinases that are reported as targets of mPgR
tested?
In the present Ms, experiments measuring Erk and phospho-Erk was conducted only to
investigate whether the mPRs expressed by NCI-H295R cells were functionally active
after stimulation with progesterone itself; therefore we measured the expression of only
one of the kinases that are part of the non-genomic progesterone effects. We are
aware that there are numerous intracellular pathways involved, as demonstrated in
several works and well revised in the paper of Segars and coworkers (Trends
Endocrinol. Metab. 28: 656-668, 2017); however, as above pointed out, the
characterization of the contribution of the different progesterone receptor components
in mediating its cytotoxic effect in ACC cells is beyond the scope of this work.
Accordingly, these observations deserve an experimental investigation that is currently
underway in the laboratory.
6)      Has progesterone been measured in the plasma of the 5 ACC patients whose
tumours were used for the primary culture work?
We did not measure the progesterone levels in patients.
7)      Clinical studies employing steroid profiling (e.g. Arlt et al, JCEM 2011; Kerkhofs
et al, Horm Cancer 2015) have revealed that most steroid-producing ACCs are
associated with excessive secretion of progesterone, yet most epidemiological studies
also suggest that steroidogenic ACCs have a more aggressive clinical course than
their non-secreting counterparts. How do the authors reconcile their findings with these
clinical observations?
The Reviewer is right, hormone hypersecretion as a whole is  associated with poorer
prognosis in ACC patients, however this negative relationship was observed  for
cortisol hypersecretion either alone or associated with androgens. We have observed
that ACC patients with pure hyperandrogenism have a better prognosis as compared
with cortisol secreting or non secreting patients (Berruti et al. Endocr Relat Cancer
2005). To our knowledge no data are available on the prognostic role of progesterone
receptor and circulating progesterone levels in ACC.
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Abstract  39 
Purpose. The management of patients with adrenocortical carcinoma (ACC) is challenging. As 40 
mitotane and chemotherapy show limited efficacy, there is an urgent need to develop therapeutic 41 
approaches. The aim of this study was to investigate the antitumor activity of progesterone and 42 
explore the molecular mechanisms underlying its cytotoxic effects in the NCI-H295R cell line and 43 
primary cell cultures derived from ACC patients.  44 
Methods. Cell viability, cell cycle and apoptosis were analyzed in untreated and progesterone-treated 45 
ACC cells. The ability of progesterone to affect the Wnt/β-catenin pathway in NCI-H295R cells was 46 
investigated by immunofluorescence. Progesterone and mitotane combination experiments were also 47 
performed to evaluate their interaction on NCI-H295R cell viability. 48 
Results. We demonstrated that progesterone exerted a concentration-dependent inhibition of ACC 49 
cell viability. Apoptosis was the main mechanism, as demonstrated by a significant increase of 50 
apoptosis and cleaved-Caspase-3 levels. Reduction of β-catenin nuclear translocation may contribute 51 
to the progesterone cytotoxic effect. The progesterone antineoplastic activity was synergically 52 
increased when mitotane was added to the cell culture medium.   53 
Conclusions. Our results show that progesterone has antineoplastic activity in ACC cells. The 54 
synergistic cytotoxic activity of progesterone with mitotane provides the rationale for testing this 55 
combination in a clinical study.  56 
 57 
Abbreviations: ACC, adrenocortical carcinoma; PgR, progesterone receptor; CI, confidence 58 
interval; MTT, 3-(4,5-Dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide; mPR, 59 
progesterone membrane receptor; PGRMC1, progesterone receptor membrane component 1. 60 
 61 
Keywords: adrenocortical carcinoma, progesterone, progesterone receptor, cell viability. 62 
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Introduction 64 
Adrenocortical carcinoma (ACC) is a rare aggressive endocrine tumor [1] that in approximately 50% 65 
of adults is capable of hormone secretion [2]. Cushing’s syndrome is the most commonly associated 66 
endocrine disorder [3]. The Systemic therapies have a limited efficacy [4-6]; thus, the prognosis of 67 
advanced ACC patients, not amenable to radical extirpation, is poor with a 5 year survival rate of 68 
15% [7]; moreover, histological and molecular diagnostic parameters are not still completely shared 69 
[8]. Mitotane (o, p′-dichlorodiphe nyldichloroethane, o, p′-DDD) is the reference drug; however, 70 
toxicity and narrow therapeutic index limit its efficacy [9]. Therefore, there is an urgent need of new 71 
therapeutic approaches. 72 
We have recently observed that abiraterone acetate (abiraterone) has both antisecretive and antitumor 73 
activities in ACC cell lines [10]. The antisecretive effect of abiraterone is mediated by the inhibition 74 
of 17alpha-hydroxylase/17,20-lyase (CYP17A1), a key enzyme for steroid hormone synthesis [11, 75 
12] leading to a rapid inhibition of cortisol secretion [10, 13]. Abiraterone mechanism of action may 76 
involve, at least in part, the Wnt/β-catenin signaling pathway [10] that is constitutively active in 77 
approximatively 30% of ACC [14] and is a potential target for new molecular therapies. The cytotoxic 78 
effect of abiraterone remains to be fully elucidated, but evidence strongly indicate that it is directly 79 
associated with the drug-induced increase of progesterone levels, requiring the activation of the 80 
intracellular progesterone receptors (PgRs). Interestingly, in addition to the well known role of PgRs 81 
as nuclear transcription factors, different members of membrane progesterone receptors (mPRs)  have 82 
been identified and the term “extranuclear” or “non-genomic” effects of progesterone was suggested 83 
to specifically defined mPR functions [15]. Another  putative membrane-specific progesterone 84 
receptor, distinct from known mPRs and nuclear PgR, was isolated from different tissues and called 85 
Progesterone Receptor Membrane Component 1 (PGRMC1) [15, 16]. The extranuclear receptor 86 
activation leads to a rapid signaling, linked to various second messenger cascades, including 87 
extracellular signal-regulated kinases (Erk 1/2, p42/44, p38 MAPKs) [15] and regulation of 88 
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intracellular calcium mobilization [16]. These effects are progesterone-dependent but independent of 89 
PgR transcriptional activity, and are integral part of progesterone cellular effects [17]. 90 
In this study, we investigated the cytotoxic effects of progesterone and the molecular mechanisms 91 
underlying its antitumor activity in NCI-H295R ACC cell line [18] and in ACC primary cell cultures 92 
derived from patients with either cortisol-secreting or non-secreting ACC. 93 
 94 
Materials and Methods 95 
Cell lines 96 
NCI-H295R ACC cell line was obtained from the American Type Culture Collection (ATCC) and 97 
cultured as suggested by the manufacturer. Cells were authenticated by the AmpFISTR Identifiler 98 
PCR amplification kit (Applied Biosystems, Foster City, CA, USA). Media and supplements were 99 
supplied by Sigma Italia (Milan, Italy). SW13 cell line was obtained from ATCC and cultured as 100 
suggested by the manufacturer. 101 
Primary cell cultures 102 
Human ACC primary cells were derived from three patients with cortisol-secreting tumors (ACC01, 103 
ACC02 and ACC16) and from two patients with non–secreting tumors (ACC03, ACC08). Clinical 104 
and histological features are reported in Table 1. After surgical removal, cells were enzymatically 105 
digested with (0.1 mg/mL) collagenase (Sigma Italia, Milan, Italy) and cultured in the same medium 106 
of NCI-H295R cells. The project was approved by the local Ethical Committee and written informed 107 
consent was obtained from all patients. 108 
Immunohistochemistry  109 
Immunohistochemistry for PgR was performed on 2 µm sections from formalin fixed-paraffin 110 
embedded ACC tissues. Ventana BenchMark Ultra platform was used according to the manufacturer's 111 
recommended settings. Ultra Cell Conditioning 1 (CC1) solution was used for heat-induced epitope 112 
retrieval (95°C for 64 min). Slides were incubated (36°C for 16 min) with the ready-to-use anti-PgR 113 
antibody (monoclonal rabbit anti-human PR clone 1E2, Roche) [19] and followed by UltraView 114 
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Universal DAB Detection Kit. Positive and negative controls from breast cancer tissue microarrays 115 
were included in the same slides. 116 
Cell treatments 117 
NCI-H295R cells and ACC primary cultures were seeded in 24-well plates and cultured in complete 118 
medium. Before treatment, culture medium was switched into charcoal-dextran-treated Nu-Serum 119 
(cNS)-medium with increasing concentrations of progesterone (0.1 - 160 µM) and/or mitotane (25 120 
nM - 40 µM) for 4 days. Both progesterone and mitotane were dissolved in DMSO. NCI-H295R cells 121 
were also exposed to mifepristone (0.1 nM – 500 nM) in combination with progesterone (25 µM) for 122 
4 days. Mifepristone and mitotane were supplied by Selleckchem Chemicals (DBA Italia, Milan, 123 
Italy) and progesterone was purchased from Sigma Italia (Milan, Italy). SW13 cells were seeded in 124 
24-well plates and cultured in complete medium. Before treatment, culture medium was switched 125 
into charcoal-dextran-treated FBS-medium with increasing concentrations of progesterone (0.1 - 100 126 
µM) for 3 days. Cell exposure to DMSO alone did not modify cell viability in any of the cell cultures 127 
used. 128 
Cell viability assay  129 
Cell viability was evaluated by 3-(4,5-Dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide 130 
(MTT) dye reduction assay according to the manufacturer’s protocol (Sigma Italia, Milan, Italy). 131 
Absorbance was measured by a spectrophotometer at 540/620 nm (GDV, Rome, Italy).  132 
Drug combination experiments  133 
Progesterone and mitotane combination experiments were performed to evaluate their interaction on 134 
NCI-H295R cell viability, according to the Chou and Talalay method [20]. Cells were treated for 4 135 
days with progesterone (0.1 - 160 µM) and mitotane alone (25 nM - 40 µM) or with progesterone in 136 
combination with mitotane at a fixed ratio  (progesterone : mitotane = 4:1), as recommended for the 137 
most efficient data analysis [21, 22]. Cells were analyzed for cell viability using MTT. Data were 138 
then converted to Fraction affected (Fa, range from 0 to 1 where Fa = 0 indicating 100% of cell 139 
viability and Fa = 1 indicating 0% of cell viability) and analyzed using the CompuSyn software 140 
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(ComboSyn inc. Paramus, NJ, USA) to calculate the Combination Index (CI), being the CI value < 141 
0.9 an indication of synergism, a CI = 0.9-1.1 an indication of additive effect and CI > 1.1 and 142 
indication of antagonism. 143 
Quantitative RT-PCR (qRT-PCR) 144 
Gene expression was evaluated by qRT-PCR (ViiA7 Real-Time PCR System, ThermoFisher 145 
Scientific, Milan, Italy), using SYBR Green as fluorochrome, as described elsewhere [23]. The 146 
sequences of sense and antisense oligonucleotide primers are listed in Supplemental Table 1. 147 
Differences  in  the threshold cycle Ct values between the beta-actin  housekeeping gene and the 148 
studied genes (ΔCt) were then calculated as an indicator of the amount of mRNA expressed. 149 
Western Blot 150 
Whole cell lysates were prepared in ice-cold buffer with protease and phosphatase inhibitor cocktails 151 
(Roche, Milan, Italy) [24]. Equal amounts of protein were separated by electrophoresis on a 4-12% 152 
NuPAGE Bis-Tris Gel System (Life Technologies, Milan, Italy) and electroblotted to a nitrocellulose 153 
membrane. Rabbit monoclonal antibody against human Caspase-3 (Cell Signaling Technology, 154 
Milan, Italy) [25] were used, both at final concentration 0.1µg/mL. The Erk protein was detected 155 
using anti-total Erk and anti-phospho-Erk antibodies (Santa Cruz Biotechnologies, Heidelberg, 156 
Germany) [26] at final concentration 0.7 µg/mL. Primary antibodies anti-mPR (0.5 µg/mL final 157 
concentration) and anti-PRGMC1 (1 µg/mL final concentration) were purchased from Abcam 158 
(Cambridge, UK) [27] and Santa Cruz Biotechnologies (Heidelberg, Germany) [28]. A mouse 159 
monoclonal antibody directed against the N-terminal region of human α-Tubulin (Sigma Italia, Milan, 160 
Italy) was used to normalize the values. Secondary HRP-labelled anti-rabbit and anti-mouse 161 
antibodies (Santa Cruz Biotechnologies, Heidelberg, Germany) were used and the specific signal was 162 
visualized by the ECL-LiteAblot Extend Long (Euroclone, Milan, Italy). Densitometric analysis of 163 
the immunoblots was performed using the GelPro-Analyzer v 6.0 (MediaCybernetics, Bethesda, MD, 164 
USA).  165 
Double staining AO/EtBr  166 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
 
NCI-H295R cells were treated with progesterone (25 M) for 4 days. A double staining with acridine 167 
orange (AO) and ethidium bromide (EtBr) was performed to visualize and quantify the number of 168 
viable, apoptotic and necrotic cells, as previously described [10]. Cells were examined by a Zeiss 169 
LSM 510 META confocal laser-scanning microscope (Carl Zeiss AG, Germany). Several fields, 170 
randomly chosen, were digitalized and scored by using the NIH Image J software. 171 
Cell cycle analyses  172 
Flow cytometric cell cycle analysis was performed as described, with minor modifications [29]. 173 
Briefly, untreated and progesterone-treated NCI-H295R cells were fixed, treated with RNase A (12.5 174 
μg/ml), stained with propidium iodide (40 μg/ml) (Sigma Italia, Milan, Italy) and analyzed by Flow 175 
Cytometry using a MACS Quant Analyzer (Miltenyi Biotec GmbH) for cell cycle status. Data were 176 
analyzed using FlowJo (TreeStar). 177 
Immunofluorescence  178 
Cells were grown onto 12 mm poly-L-lysine coated coverslips and treated with IC50 value of 179 
progesterone for 3 days, with or without mifepristone (100 nM). Cells were then fixed in 4% 180 
paraformaldehyde for 20 min and permeabilized with 0.2% Triton X-100 in PBS for 1 hr. 181 
Nonspecific binding was blocked by incubation in PBS containing 0.2% Triton X-100 and 10% 182 
normal goat serum for 1 hr. Cells were then incubated overnight at 4°C with anti-β catenin primary 183 
antibody (14.2 ng/mL, Cell Signaling Technologies, Milan, Italy). After extensive washes, the Alexa 184 
Fluor488 anti-rabbit secondary antibody (Life Technologies, Milan, Italy) was applied for 1 hr at 185 
room temperature, followed by counterstaining with Hoechst (Sigma Aldrich, Milan, Italy) for 5 min. 186 
After rinsing in PBS, coverslips were mounted using FluorPreserveTM Reagent and cell staining was 187 
detected using a Zeiss LSM 510 META confocal laser-scanning microscope (Carl Zeiss AG, 188 
Oberkochen, Germany). NIH-ImageJ software was used for image analysis and processing. 189 
Statistical Analysis  190 
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Statistical analysis was carried out using GraphPad Prism software (version 5.02, GraphPad Software, 191 
La Jolla, CA, USA). One-way ANOVA with Bonferroni׳s correction was used for multiple 192 
comparisons. Unless otherwise specified, data are expressed as mean ± S.E.M. of at least three 193 
experiments run in triplicate. P values < 0.05 were considered statistically significant. 194 
 195 
Results 196 
Progesterone effects on NCI-H295R cell viability  197 
The predominant expression of the intracellular full length PgR B isoforms was previously described 198 
in NCI-H295R cells [10]. The exposure of NCI-H295R cells to increasing concentrations of 199 
progesterone (0.1 - 160 µM) for 4 days led to a reduction in NCI-H295R cell viability in a 200 
concentration-dependent manner (Fig.1a). Sigmoidal concentration-response function was applied to 201 
calculate the IC50 value of progesterone in NCI-H295R cells, which was 25.5 μM (95% confidence 202 
interval [CI], 19.9 to 32.9). Time course experiments in NCI-H295R cells treated with progesterone 203 
at the IC50 value demonstrated that the reduction of cell viability reached its maximum at 4 days, with 204 
no significant change up to 6 days (IC50 value of 29.6 µM; 95% CI 23.6 to 37.0) (data not shown). 205 
Pretreatment of NCI-H295R cells with increasing concentration of the PgR antagonist mifepristone 206 
(0.1 -500 nM) antagonized the cytotoxic effect elicited by progesterone at its IC50 for 4 days (Fig.1b). 207 
This provides evidence that the antineoplastic activity of progesterone requires the stimulation of the 208 
PgRs. Mifepristone alone (0.1 – 500 nM; 4 days) did not affect NCI-H295R cells viability (data not 209 
shown).  210 
Progesterone induces NCI-H295R cells apoptosis, without inducing changes in the cell cycle 211 
distribution 212 
To provide explanation on the mechanism underlying the progesterone-induced NCI-H295R cell 213 
toxicity, cells were treated with progesterone (25 μM; 4 days) and stained with AO/EtBr. 214 
Progesterone deeply increased the number of apoptotic cells 39 ± 2%; while necrotic and living cells 215 
were 2 ± 2% and 59 ± 3% respectively (apoptotic cells: untreated vs treated cells: P < 0.001 Fig.2a). 216 
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Time-course experiments were conducted and our results demonstrated that after 2 days of treatment, 217 
the effect is as follow: 93 ± 1% living cells, 7 ± 1% apoptotic cells and no necrotic cells (apoptotic 218 
cells: untreated vs treated cells: P < 0.05; Supplemental Fig.1a). Progesterone-induced apoptotic 219 
cytotoxicity reached its maximum after 4 days of treatment, as above indicated, and it was not 220 
modified if cells were exposed to progesterone up to 6 days: 47 ± 1% living cells, 43 ± 3% apoptotic 221 
cells, 10 ± 1% necrotic cells (apoptotic cells: untreated vs treated cells: P < 0.001; Supplemental 222 
Fig.1b). We next examined the expression of total Caspase-3 and the cleaved-Caspase-3, that play a 223 
central role in the execution phase of cell apoptosis [30], in progesterone-treated NCI-H295R cells in 224 
comparison to untreated cells (Fig.2b). Progesterone exposure for 48 hrs significantly increased the 225 
expression of cleaved-Caspase-3 (% of increase: 23.9 ± 1.6) while total Caspase-3 levels were not 226 
affected. The analyses of the cell cycle progression by flow cytometry in untreated and progesterone-227 
treated NCI-H295R cells did not show significant differences in cell distribution up to 4 days of 228 
treatment (Fig.2c). However, we observed that treatment with progesterone for 4 days increased the 229 
proportion of cells in the sub-G0 phase: 29.7 ± 4.6% untreated cells, 50.3 ± 5.1% progesterone-treated 230 
cells (P < 0.05), suggestive of DNA fragmentation. Taken together these observations suggest that 231 
apoptosis is the main mechanism mediating the progesterone cytotoxicity.  232 
Effect of progesterone on -catenin nuclear translocation in NCI-H295R cells  233 
NCI-H295R cells were treated with progesterone and analyzed for -catenin localization using 234 
immunofluorescence analyses. At baseline, β-catenin was highly expressed in the nucleus (Fig.3a), 235 
whereas the cell exposure to progesterone at its IC50 reduced -catenin nuclear localization and 236 
increased its retention into cytoplasm (Fig.3b). The effect of progesterone in sequestering -catenin 237 
in cytoplasm was counteracted by 100 nM mifepristone (Fig.3c). Immunofluorescence quantification 238 
using ImageJ software, reported in Table 2, demonstrated that progesterone significantly reduced -239 
catenin nuclear localization. The progesterone-induced reduction of nuclear β-catenin induced the 240 
decrease of mRNA expression of some of its target genes, namely MYC and survivin, while the 241 
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mRNA expression level of another gene, CCND1, resulted unchanged by progesterone treatment 242 
(Supplemental Fig.2).  243 
mPR and PGRMC1 244 
As underlined in the Introduction, accumulating evidence suggests that rapid progesterone responses 245 
are mediated by activation of mPRs [31]. In order to evaluate whether or these receptors could 246 
contribute to the observed progesterone cytotoxic effect on NCI-H295R, we firstly evaluated their 247 
expression. As shown in Supplemental Fig.3a, NCI-H295R expressed mPRs. These receptors were 248 
functionally active, as, when cells were treated with the IC50 value of progesterone, we observed a 249 
reduction of phospho-Erk protein level (% of decrease: 30.39 ± 1.14) at very early time, namely 15’ 250 
after progesterone exposure (Supplemental Fig.3b). Finally, we demonstrated that NCI-H295R 251 
expressed as well the PGRMC1 (Supplemental Fig.3a).  252 
Progesterone enhanced NCI-H295R cytotoxicity induced by mitotane in drug-combination 253 
treatments 254 
To evaluate whether progesterone treatment of NCI-H295R cells could enhance the cytotoxicity of 255 
mitotane, the combination index (CI) was calculated according to the Chou-Talalay method [21]. 256 
NCI-H295R cells were firstly exposed to increasing concentrations of mitotane (25 nM - 40 M) for 257 
4 days and analyzed for cell viability by MTT assay. Sigmoidal concentration-response function was 258 
used to calculate the IC50 value, which was 3 μM (95% CI, 2.08 to 4.34) (Fig.4a). The cytotoxic effect 259 
of progesterone in combination with mitotane was evaluated at the 1:4 fixed molar ratio for 4 days 260 
(Fig.4b). We found that in NCI-H295R cells, the combination had a synergistic cytotoxic effect as 261 
compared to each single compound at a Fa = 0.09 - 0.86 with range of CI: 0.08 to 0.88 (Fig.4c).  262 
Progesterone exerted cytotoxic effect in primary human ACC cells  263 
Primary cultures derived from ACC patients were treated with increasing concentrations of 264 
progesterone for 4 days and analyzed for cell viability by MTT assay. In cortisol-secreting ACC cells 265 
(ACC01, ACC02 and ACC16), progesterone exerted a concentration-dependent inhibition of cell 266 
viability with IC50 values of 18 μM (95% CI 11.4 to 31.7), 32.9 μM (95% CI 26.5 to 40.9) and 39.2 267 
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μM (95% CI 31.8 to 48.4) respectively. Immunohistochemical analyses of PgR expression in ACC01, 268 
ACC02 and ACC16 tumors showed that at least 40% of neoplastic cells were positive for PgR (Table 269 
1). By contrast, a lesser cytotoxic effect of progesterone was observed in the non-secreting human 270 
ACC cells, ACC03 and ACC08, with IC50 values of 73.4 μM (95% CI 46.1 to 116.8) and 80.8 μM 271 
(95% CI 50.5 to 129.5) respectively (Fig.5). PgR expression in these cells was detected in less than 272 
5% of ACC cells (Table 1).  273 
Progesterone effect on SW13 cell line. 274 
Finally, as an internal control, we tested the effect of progesterone in the non steroidogenic SW13 275 
cell line, that belongs from a small cell carcinoma of adrenal and which exact histopathological 276 
features are still under investigation [32]. We firstly analyzed the mRNA expression of PgRs and 277 
results indicated that SW13 cells were devoid of PgR: indeed, q-RT-PCR analysis revealed  a not 278 
detectable PgR mRNA expression in this cell line compared to the ΔCt of 9.01 ± 0.25 in NCI-H295R 279 
cells, used as positive control. The western blot analysis of mPR and PGRMC1 expression in SW13 280 
cell line indicated that these receptor proteins were expressed in this cell line (Supplemental Figure 281 
4a). When exposed to increasing concentrations of progesterone within the same range of 282 
concentrations used for NCI-H295R cells, a cytotoxic effect could be observed, although it was non 283 
concentration-dependent (Supplemental Fig.4b).  284 
 285 
Discussion 286 
In the present study, we demonstrated that progesterone, through its receptors, exerted a 287 
concentration-dependent and time-dependent inhibition of ACC cell viability, and this effect was, at 288 
least in part, counteracted by the PgR antagonist mifepristone. The role of PgR is further supported 289 
by data published by our group, where the PgR silencing induces the almost complete disappearance 290 
of the effect of abiraterone on cell viability [10]. The cytotoxic effect of progesterone was observed 291 
in the NCI-H295R cells, an ACC cell line that mainly express the full length PgR B isoform [10, 33] 292 
and confirmed in primary cell cultures derived from cortisol-secreting ACC that are characterized by 293 
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a marked expression of the PgR. Indeed, the cytotoxic effect of progesterone was less evident in non-294 
secreting ACC tumors in which PgR expression was low. Intriguingly, we demonstrated that NCI-295 
H295R cells expressed also the mPR and PGRMC1 component, suggesting that the progesterone 296 
effects that we observed in ACC cells, both in cell line and primary cultures, could be a result of a 297 
multifactorial process involving both genomic and non-genomic actions, dependent on  both 298 
membrane and intracellular progesterone receptor arrangement expressed by each ACC tumor. The 299 
scenario is even more complex than expected, in light of the evidence showing that the different effect 300 
of progesterone depends on many variables, such as the type of cells, the genomic and/or non genomic 301 
effects linked to the progesterone receptor expression and the concentration of hormone present [34]. 302 
As a matter of fact , we observed that the non steroidogenic SW13 cell line, established from a small 303 
cell carcinoma of the adrenal [35], was responsive to the cytotoxic effect of progesterone (although 304 
without displaying  a concentration-dependent curve ) despite they expressed only mPR and 305 
PGRMC1. On the basis of these preliminary results the characterization of expression and function 306 
of all receptor components of progesterone pathway in our experimental models is now undergoing 307 
in our  lab. 308 
 The present  results confirm and extend our previous study [10] showing that the in vitro 309 
antineoplastic activity of abiraterone is mediated by the drug-induced increase in progesterone levels. 310 
PgRs,therefore,  could represent a novel promising target in the management of  ACC. 311 
In PgR-positive breast cancer cell lines, progestins can induce a growth arrest due to decreased 312 
expression and activity of cyclin-dependent kinase (cdk) complexes [36]. In the present study, we 313 
showed that the progesterone-induced cytotoxicity of NCI-H295R ACC cells was not cell cycle 314 
mediated, but apoptosis represented the main molecular events, with a significant increase of the 315 
proapoptotic cleaved-Caspase-3 levels in the initial phase of the treatment. The ability of progesterone 316 
in modulating apoptotic events, both in vitro and in vivo, was previously demonstrated in several 317 
tumor cells [37-41]. On the light of these results, we therefore explored the possible molecular 318 
mechanism regulating the progesterone-induced apoptosis in ACC.  319 
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The Wnt/β-catenin pathway is frequently altered in ACC, which is characterized by CTNNB1 320 
mutations leading to β-catenin accumulation in the nucleus, where it binds with the T cell factor (Tcf) 321 
and enhances its transcriptional activity. In the NCI-H295R cell line, harboring the activating 322 
CTNNB1 p.S45P mutation, we found that progesterone treatment partially inhibited the β-catenin 323 
translocation into the nucleus, thus suggesting the involvement of this pathway in the progesterone 324 
antineoplastic activity. These data are in line with our previous in vitro experiments showing that the 325 
increased levels of progesterone in NCI-H295R cell culture microenvironment, induced by the block 326 
of the CYP17A1 by abiraterone, significantly inhibited the β-catenin migration into the nucleus. 327 
Further evidence comes from studies showing that progesterone is able to inhibit the Wnt/β-catenin 328 
pathway in endometrial carcinoma [42]. The functional effect of the β-catenin modification of 329 
traslocation is the  down-regulation of the expression of some β-catenin target genes, namely MYC 330 
and survivin, while CCND1 was not modified.  331 
Taken together these data are suggestive for an involvement of β-catenin inhibition in the 332 
progesterone induced apoptosis of ACC cells. These data, however, are not exhaustive and the full 333 
evidence of the inhibitory effect would require the demonstration of a modulation of the expression 334 
of other specific β-catenin target genes in NCI-H295R cells by progesterone treatment. These further 335 
experiments are outside the scope of the present paper and will be a matter of a future study.  336 
Finally, the in vitro demonstration of the synergistic cytotoxic effect of the combination mitotane + 337 
progesterone could be of considerable interest for its possible clinical application, as progesterone 338 
and its derivatives are already part of the supportive  approach in cancer patients . These preclinical 339 
data provides the rationale  for a new trial  testing the efficacy of progesterone n association with 340 
current systemic therapies in the management of ACC patients.  341 
In conclusion, the present study shows that progesterone exerts a cytotoxic activity in ACC cells, by 342 
inducing apoptosis via activation of the progesterone receptors. Both the genomic and non-genomic 343 
effects of progesterone seemed to mediate the cytotoxicity, although this point is still under 344 
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investigation. The synergistic cytotoxic activity of progesterone with mitotane provides the rationale 345 
for testing this combination in a prospective clinical study.  346 
 347 
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Figure Legends 479 
 480 
Fig. 1: Cytotoxic effect of progesterone in NCI-H295R cells. a. NCI-H295R cells were treated with 481 
increasing concentration of progesterone (0.1-160 μM) for 4 days. Cell viability was analyzed by 482 
MTT assay. Results are expressed as percent of viable cells vs control (ctrl) cells. Data are the mean 483 
± S.E.M. of three experiments performed in triplicate. **P < 0.001 vs ctrl. b. Cells were treated with 484 
progesterone (25 μM) for 4 day in the presence of the PgR antagonist mifepristone (0.1 nM – 500 485 
nM). Cell viability was analyzed by MTT assay. Results are expressed as percent of viable cells vs 486 
control (ctrl) cells. Data are the mean ± S.E.M. of three experiments performed in triplicate. **P < 487 
0.001 vs ctrl.  488 
Fig. 2: Progesterone promotes apoptotic events in NCI-H295R cells, with no influences on cell 489 
cycle phases. a. NCI-H295R cells were treated with progesterone (25 µM) for 4 days. Untreated (C) 490 
and progesterone-treated (T) cells were then stained with AO/EtBr. Viable (green), apoptotic (yellow) 491 
and necrotic (red) cells were scored under a confocal laser-scanning microscope. Magnification, 10x. 492 
The images were representative of at least three independents experiments, with superimposable 493 
results. b. Cells were treated with progesterone (25 µM) for 1-3 days and analysed for Caspase-3 and 494 
clevead-Caspase-3 expression using Western Blot (WB). The human α-Tubulin was used as internal 495 
control. A representative WB is shown. Densitometric analysis of blots (n = 3) with specific levels of 496 
cleaved-Caspase-3 normalized to the corresponding tubulin levels. Bars represent the mean ± S.E.M. 497 
**P < 0.01 vs untreated cells. c. NCI-H295R cells were treated with progesterone (25 µM), stained 498 
with propidium iodide and analyzed for DNA content by flow cytometry. Histograms representative 499 
of one out of three experiments were shown in the figure.  500 
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Fig. 3: Progesterone treatment affects the subcellular localization of -catenin in NCI-H295R 501 
cells. Cells were treated with progesterone (25 µM) alone or in combination with mifepristone (100 502 
nM) for 3 days. Untreated (a), progesterone-treated (b) progesterone-mifepristone-treated (c) cells 503 
were analyzed for β-catenin localization following by incubation with Hoechst for nuclear staining. 504 
Panels a, d, g: Hoechst; panel b, e, h: -catenin; panel c, f, i: merge. The scale bar of 50 µm is 505 
automatically inserted by the software ZEN Black. 506 
Fig. 4: Effect of the combination of progesterone with mitotane in NCI-H295R cells. a. NCI-507 
H295R cells were treated with increasing concentration of mitotane (25 nM - 40 μM) for 4 days. Cell 508 
viability was analyzed by MTT assay. Results are expressed as percent of viable cells vs control (ctrl) 509 
cells. Data are the mean ± S.E.M. of three experiments performed in triplicate. **P < 0.001 vs ctrl. 510 
b. NCI-H295R cells exposed to increasing concentrations of progesterone and mitotane alone or in 511 
combination at fixed concentration at 1:4 molar ratio (progesterone: mitotane) for 4 days. Data are 512 
expressed as percent of viable cells vs control (ctrl) cells. Data are the mean ± S.E.M. of three 513 
experiments performed in triplicate. c. Cell viability from B was converted to Fraction affected (Fa) 514 
values and resulting data were analyzed with CompuSyn software to obtain combination index (CI) 515 
plot. Fa = 0, 100% cell viability; Fa = 1, 0% cell viability; CI value < 0.9, synergism, CI = 0.9-1.1 516 
additive effect and CI > 1.1 antagonism. 517 
Fig. 5: Cytotoxic effect of progesterone in human ACC primary cultures. Cortisol secreting 518 
ACC01 (), ACC02 (■), ACC16 (▲) and non secreting ACC03 (○), ACC08 () primary cultures of 519 
human ACC cells were treated with increasing concentrations of progesterone (0.1 – 100 µM) for 4 520 
days. Cell viability was evaluated by MTT assay. Results are expressed as percent of viable cells vs 521 
control (ctrl) cells. Data are the mean ± S.E.M. of three independent experiments performed in 522 
triplicate. *P < 0.01 vs ctrl; **P < 0.001 vs ctrl.  523 
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Table 1: Clinical characteristics of ACC patients. 
Primary culture 
identification 
Tumor 
specimen 
Histology Disease stage Hormone 
hypersecretion 
PgR 
expression 
ACC01 
Female  
66 yr old 
Primary 
ACC 
Weiss score 8  
Mitotic 
index: >50/50 
HPF Ki67 70% 
Stage IV (hepatic 
metastases) 
Cortisol (severe 
Cushing’s syndrome) 
40% 
ACC02 
Female  
63 yr old 
Peritoneal 
metastases 
Weiss score not 
available 
Mitotic 
index: >50/50 
HPF Ki67 50%  
Stage IV (peritoneal 
dissemination) 
Cortisol (mild clinical 
signs of 
hypercortisolism) 
70% 
ACC16 
Male 
55 yr old 
Primary 
ACC 
Weiss score not 
available  
Mitotic index: 
10/50 HPF Ki67 
50% 
Stage IV 
(bone and multiple 
abdominal 
lymphonodal 
metastases) 
Cortisol (severe 
Cushing’s syndrome) 
40% 
ACC03 
Male 
59 yr old 
Local 
relapse of 
ACC 
Weiss score 8  
Mitotic index: 
25/50 HPF Ki67 
20% 
Stage IV (left 
hypochondrium soft 
tissue relapse and 
peritoneal 
dissemination) 
No secretion 3-5% 
ACC08 
Female 
50 yr old 
Lung 
metastases 
Weiss score 8  
Oncocytic 
features  
Mitotic index: 
10/50 HPF Ki67 
20%  
Stage IV (lung and 
bone metastases) 
No secretion 1-2% 
 
Table
Table 2. Immunofluorescence quantification of β-catenin expression.  
  % mean  ± SEM 
Untreated cells 
nucleus 51.06 ± 2.3 
citoplasm 48.94 ± 2.3 
Progesterone-treated cells 
nucleus 29.01 ± 3.1 
citoplasm 70.99 ± 3.9 * 
Progesterone –treated cells in 
the presence of mifepristone 
nucleus 54.20 ± 2.3 
citoplasm 45.80 ± 2.6 
  
Cells were treated with progesterone (25 µM) alone or in combination with mifepristone (100 nM) for 3 days. 
Quantification was performed using the ImageJ software. Several cells in different fields, randomly chosen, were 
quantified. *P < 0.001 vs nuclear localization 
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